In November 2025, the headlines were everywhere: the warning had come off HRT. Friends forwarded the news, group chats lit up, and women who had spent years feeling nervous about their patches and gels wondered whether they had been worrying for nothing. Others felt the opposite, suspicious that something so serious could simply vanish overnight.
Both reactions make sense. What actually happened is more specific, and more interesting, than the headlines suggested. It mostly affects the packaging of HRT in the United States, and very little about how HRT is prescribed in the UK. But it does mark a real shift in how regulators talk about menopause treatment, and it's worth understanding what changed, what didn't, and what it means if you're taking HRT or thinking about it.
In the US, the strongest safety warning a medicine can carry is a boxed warning, often called a black box warning. It sits in a heavy black border at the very top of the prescribing information, above everything else. It's meant to be impossible to miss, and it's usually reserved for serious or life-threatening risks.
Since the early 2000s, almost every menopausal hormone product in the US carried one. It warned about heart disease, stroke, breast cancer, probable dementia and, for oestrogen taken without a progestogen, cancer of the womb lining. It also told doctors to use the lowest dose for the shortest time. For more than two decades, that box was the first thing many women and their doctors read about HRT.
The box was added after the Women's Health Initiative, a large American trial whose first results were published in JAMA in 2002. The combined HRT part of the trial was stopped early when it showed a small rise in breast cancer, heart attacks, strokes and blood clots. The news went around the world within days, and HRT prescriptions fell sharply in many countries, including the UK.
What got lost was who was in the trial. The average participant was 63, many were more than a decade past menopause, and most had no symptoms at all. They were taking an older form of oral HRT that is now rarely used in the UK. Later reanalyses showed that the picture is more reassuring for women who start HRT under 60 or within 10 years of menopause, which is exactly the group most likely to be offered it today. There's more on this in the truth about HRT.
On 10 November 2025, the US Food and Drug Administration announced that it was starting to remove most of the boxed warning from menopausal hormone therapy. Here's what it asked manufacturers to do:
This hasn't happened overnight. Each manufacturer has to submit new labelling for approval. The first six products had their updated labels approved in February 2026, and three more estradiol patches followed at the end of October 2026, bringing the total to nine. Around 30 companies have submitted changes so far, so for a while American pharmacies will stock a mix of old and new packaging for the same kind of medicine.
A label is not the same thing as the evidence underneath it. The risks of HRT are still real; they're simply described with more context. These are the points that matter most:
Most menopause specialists agreed that the old warning was out of date. The disagreement was about how the change was made. The FDA didn't hold a formal advisory committee meeting, which is the usual way such decisions are reviewed. Instead, it held a televised expert panel, and critics, including Professor Rod Baber, a past president of the International Menopause Society, called the process unusual and the choice of panellists controversial.
Some of the figures used to announce the change also worried doctors. The US health department said HRT was associated with a 50% lower risk of heart attacks and a 35% lower risk of Alzheimer's disease. Those numbers come largely from observational studies, which can't prove cause and effect, and they're relative figures that sound much larger than the absolute change for any one woman. UK guidance is far more cautious. NICE, for example, says HRT shouldn't be offered to prevent heart disease or dementia, and notes that combined HRT started at 65 or over might slightly increase dementia risk. We look at the dementia research in detail in HRT and dementia.
So the honest summary is this: removing an outdated warning was overdue, but that doesn't mean HRT has been shown to protect your heart or brain. It means the risks are now presented more fairly for the women most likely to use it.
The UK doesn't use US-style boxed warnings. British medicines come with a summary of product characteristics for prescribers and a patient information leaflet in the box, and neither has a black border at the top. The FDA's decision doesn't change any UK leaflet, and it doesn't change what your GP is allowed to prescribe.
In practice, UK guidance moved in the same direction years ago. NICE's menopause guideline, updated in 2024, sets no arbitrary limit on how long you can take HRT, and recommends a yearly review rather than a five-year cut-off. It gives doctors tables of absolute risk to share with patients, and it notes that HRT through the skin doesn't raise the risk of blood clots. The British Menopause Society says much the same. If you were told years ago that you had to stop at five years, or at 60, that advice is out of date in the UK too, and our guide to stopping HRT explains why.
Where you might notice a difference is online. A lot of the menopause content on social media is American, and some of it now describes HRT as though it were risk-free. It isn't, and neither is it the danger the old box implied.
For many women, the most useful thing about this change is that it may make the conversation easier. If fear of the old warning was what stopped you asking, this is a good time to have that conversation again. A few things are worth bringing to the appointment:
Nothing you need to do changes. Keep taking your HRT as prescribed and keep up with your yearly review. If you were on the lowest possible dose purely because of the old "lowest dose, shortest time" advice and your symptoms aren't controlled, that's a reasonable thing to raise with your doctor, as UK guidance already allows the dose to be adjusted to what works for you. Keep going to breast screening when you're invited, and keep reporting any unexpected bleeding. If side effects are bothering you, HRT side effects explains what can be adjusted.
Does this mean HRT is completely safe now?
No. It means the warning now reflects the evidence more fairly. For most healthy women under 60 with symptoms, the benefits of HRT outweigh the risks, but there are still risks, and they're different for every woman.
Has the UK removed any warnings from HRT?
The UK doesn't use boxed warnings, so there was nothing equivalent to remove. UK leaflets still list the risks, as all medicine leaflets do. Prescribing in the UK is guided by NICE and the British Menopause Society, whose advice already matched much of what the FDA has now adopted.
Is vaginal oestrogen affected?
In the US, its labelling has been simplified because the old warnings were written for tablets and didn't reflect how little oestrogen reaches the bloodstream from low-dose vaginal treatments. In the UK, low-dose vaginal oestrogen has long been considered very low risk, and one brand of vaginal tablet has been available from pharmacies without a prescription since 2022, for women over 50 whose periods stopped at least a year ago. Our article on vaginal dryness explains the options.
I'm over 60. Can I still start HRT?
It isn't ruled out, but starting HRT more than 10 years after menopause, or after 60, needs a more careful look at your heart and clot risk, and a patch or gel is usually preferred. Talk it through with your GP or a menopause specialist.
Sources: US Department of Health and Human Services, Fact sheet: FDA initiates removal of black box warnings from menopausal hormone replacement therapy products, 10 November 2025 · US Food and Drug Administration, approved labelling changes for menopausal hormone therapy products, February and October 2026 · Rossouw JE et al, JAMA, 2002, Women's Health Initiative · NICE, Menopause: identification and management (NG23), updated 2024 · Medicines and Healthcare products Regulatory Agency, Drug Safety Update, HRT and breast cancer risk, 2019 · Collaborative Group on Hormonal Factors in Breast Cancer, The Lancet, 2019 · Educational only, not medical advice.
Keep reading: The truth about HRT · HRT side effects · Stopping HRT · HRT and dementia · HRT, breast density and mammograms · All about HRT